0001556247-13-000004.txt : 20130919 0001556247-13-000004.hdr.sgml : 20130919 20130919171624 ACCESSION NUMBER: 0001556247-13-000004 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20130917 FILED AS OF DATE: 20130919 DATE AS OF CHANGE: 20130919 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: REGENERON PHARMACEUTICALS INC CENTRAL INDEX KEY: 0000872589 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 133444607 STATE OF INCORPORATION: NY FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 777 OLD SAW MILL RIVER RD CITY: TARRYTOWN STATE: NY ZIP: 10591-6707 BUSINESS PHONE: 9143477000 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Van Plew Daniel P CENTRAL INDEX KEY: 0001411984 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-19034 FILM NUMBER: 131106138 MAIL ADDRESS: STREET 1: REGENERON PHARMACEUTICALS, INC. STREET 2: 777 OLD SAW MILL RIVER ROAD CITY: TARRYTOWN STATE: NY ZIP: 10591 4 1 edgardoc.xml PRIMARY DOCUMENT X0306 4 2013-09-17 0 0000872589 REGENERON PHARMACEUTICALS INC REGN 0001411984 Van Plew Daniel P 777 OLD SAW MILL RIVER ROAD TARRYTOWN NY 10591 0 1 0 0 SVP & Gen Mgr IOPS Common Stock 2013-09-17 4 M 0 52500.0 16.8 A 63236 D Common Stock 2013-09-17 4 F 0 2992.0 294.75 D 60244 D Common Stock 2013-09-17 4 F 0 25531.0 294.75 D 34713 D Common Stock 2013-09-18 4 S 0 3777.0 298.28 D 30936 D Common Stock 2013-09-18 4 S 0 2800.0 299.34 D 28136 D Common Stock 2013-09-18 4 S 0 2600.0 300.62 D 25536 D Common Stock 2013-09-18 4 S 0 1400.0 301.42 D 24136 D Common Stock 2013-09-18 4 S 0 600.0 303.01 D 23536 D Common Stock 2013-09-18 4 S 0 1444.0 304.16 D 22092 D Common Stock 2013-09-18 4 S 0 3556.0 305.14 D 18536 D Common Stock 2013-09-18 4 S 0 3600.0 306.4 D 14936 D Common Stock 2013-09-18 4 S 0 3200.0 307.28 D 11736 D Common Stock 2013-09-18 4 S 0 1000.0 308.26 D 10736 D Common Stock 1363 I By 401(k) Plan Non-Qualified Stock Option (right to buy) 16.8 2013-09-17 4 M 0 52500.0 0.0 D 2011-12-31 2018-12-17 Common Stock 52500 0 D Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Represents volume-weighted average price of sales of 3,777 shares of Company stock on September 18, 2013 at prices ranging from $297.77 to $298.78. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on September 18, 2013 at each separate price. Represents volume-weighted average price of sales of 2,800 shares of Company stock on September 18, 2013 at prices ranging from $298.87 to $299.85. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on September 18, 2013 at each separate price. Represents volume-weighted average price of sales of 2,600 shares of Company stock on September 18, 2013 at prices ranging from $299.93 to $300.93. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on September 18, 2013 at each separate price. Represents volume-weighted average price of sales of 1,400 shares of Company stock on September 18, 2013 at prices ranging from $300.96 to $301.92. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on September 18, 2013 at each separate price. Represents volume-weighted average price of sales of 600 shares of Company stock on September 18, 2013 at prices ranging from $302.53 to $303.48. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on September 18, 2013 at each separate price. Represents volume-weighted average price of sales of 1,444 shares of Company stock on September 18, 2013 at prices ranging from $303.76 to $304.59. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on September 18, 2013 at each separate price. Represents volume-weighted average price of sales of 3,556 shares of Company stock on September 18, 2013 at prices ranging from $304.77 to $305.74. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on September 18, 2013 at each separate price. Represents volume-weighted average price of sales of 3,600 shares of Company stock on September 18, 2013 at prices ranging from $305.88 to $306.78. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on September 18, 2013 at each separate price. Represents volume-weighted average price of sales of 3,200 shares of Company stock on September 18, 2013 at prices ranging from $306.96 to $307.87. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on September 18, 2013 at each separate price. Represents volume-weighted average price of sales of 1,000 shares of Company stock on September 18, 2013 at prices ranging from $307.97 to $308.72. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on September 18, 2013 at each separate price. The option became exercisable with respect to all shares underlying the option on December 31, 2011, based upon the satisfaction by the company of certain performance criteria during the period ended December 31, 2011. /s/**Daniel P. Van Plew 2013-09-19